Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH DIRECTOR WYNGAARDEN LEAVING NIH AUGUST 1

Executive Summary

NIH DIRECTOR WYNGAARDEN LEAVING NIH AUGUST 1; newly appointed HHS Assistant Secretary for Health James Mason will chair a search committee for the new NIH director. Wyngaarden announced his resignation, which was requested by President Bush, at a senior staff meeting on April 20. Wyngaarden became the twelfth director of the agency in 1982. Prior to his appointment as NIH director, Wyngaarden was professor and chairman of the Department of Medicine at Duke University, a post he had held since 1967. Before joining Duke, Wyngaarden spent several years at NIH. From 1953-54, he was a research associate at what was then the National Heart Institute, and from 1954-56, he was a clinical associate at the former National Institute of Arthritis and Metabolic Diseases. Wyngaarden is known as an authority on the regulation of purine biosynthesis and the genetics of gout. He served on several NIH study groups and review panels prior to becoming NIH director; he was also a consultant to the Office of Science and Technology from 1966 to 1972, and a member of the President's Science Advisory Committee from 1972 to 1973. A successor to Wyngaarden has not been named, but National Institute of Allergy and Infectious Diseases Director Anthony Fauci has been rumored for months to be a leading candidate.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel